These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 9250266)

  • 1. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.
    Bucher HC; Guyatt GH; Griffith LE; Walter SD
    J Clin Epidemiol; 1997 Jun; 50(6):683-91. PubMed ID: 9250266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
    Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to interpret an overview: a meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
    Easterbrook PJ
    Genitourin Med; 1997 Apr; 73(2):139-43. PubMed ID: 9215100
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials].
    Saillourglénisson F; Chêne G; Salmi LR; Hafner R; Salamon R
    Rev Epidemiol Sante Publique; 2000 Jan; 48(1):17-30. PubMed ID: 10740082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
    Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
    Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
    El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
    N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis carinii pneumonia following discontinuation of primary prophylaxis despite highly active antiretroviral therapy.
    Mammen-Tobin A; Monteiro EF
    Int J STD AIDS; 2000 Jan; 11(1):64-5. PubMed ID: 10667904
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.
    Green H; Paul M; Vidal L; Leibovici L
    Mayo Clin Proc; 2007 Sep; 82(9):1052-9. PubMed ID: 17803871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
    Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
    Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
    AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
    Chêne G; Morlat P; Leport C; Hafner R; Dequae L; Charreau I; Aboulker JP; Luft B; Aubertin J; Vildé JL; Salamon R
    Control Clin Trials; 1998 Jun; 19(3):233-48. PubMed ID: 9620807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Bender MA; Sax PE
    N Engl J Med; 2001 May; 344(21):1639; author reply 1640-1. PubMed ID: 11374364
    [No Abstract]   [Full Text] [Related]  

  • 15. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
    Green H; Paul M; Vidal L; Leibovici L
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005590. PubMed ID: 17636808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia.
    Gatti G; Fioredda F; Lorusso C; Cruciani M; Bassetti D
    Pediatr Infect Dis J; 1996 Feb; 15(2):183-4. PubMed ID: 8822303
    [No Abstract]   [Full Text] [Related]  

  • 20. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.